USPTO serial 79347676
SHIELDED-CELL & IMMUNOTHERAPY PAIRS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- PINO, BRIAN
- Law office
- TMO LAW OFFICE 114 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with SHIELDED-CELL & IMMUNOTHERAPY PAIRS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical products for gene and cell therapy | ACTIVE | — |
| 042 | Pharmaceutical research and development services in the fields of gene therapy and cell therapy; medical and pharmaceutical research and development services, all in the fields of gene therapy and cell therapy; research services relating to pharmaceutical products for gene and cell therapy; biochemistry research services relating to cell therapy and gene therapy | ACTIVE | — |
| 044 | Gene and cell therapy services; consultant services in the fields of gene therapy and cell therapy | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 9, 2024 | FINT | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Oct 24, 2024 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Oct 24, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Feb 13, 2024 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jan 24, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 24, 2024 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Oct 23, 2023 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Oct 23, 2023 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Oct 23, 2023 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| May 2, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Apr 6, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Apr 6, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Feb 18, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Feb 17, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 10, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 23, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 19, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 18, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |